LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Listă Acțiuni・Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc

Închisă

SectorSănătate

437.05 -2.98

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

434.99

Maxim

452.74

Indicatori cheie
By Trading Economics
Venit	-160M 1B
Vânzări	-240M 3B
P/E Medie Sector	25.842 51.415
EPS	4.47
Marjă de profit	34.531
Angajați	6,400
EBITDA	-215M 1.1B

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+25.51% upside

Dividende
By Dow Jones
Următoarele câștiguri	3 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	2.1B 110B
Deschiderea anterioară	440.03
Închiderea anterioară	437.05

Sentimentul știrilor

By Acuity

15%

85%

20 / 345 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

428.545 / 498.65 Suport & Rezistență

Vertex Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 mai 2026, 20:57 UTC

Câștiguri

Vertex Pharmaceuticals Posts Higher 1Q Profit

12 feb. 2026, 21:47 UTC

Câștiguri

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

3 nov. 2025, 21:44 UTC

Câștiguri

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

5 aug. 2025, 00:05 UTC

Acțiuni populare

Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl

4 aug. 2025, 21:21 UTC

Câștiguri

Principalele dinamici ale pieței

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 aug. 2025, 20:45 UTC

Câștiguri

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 mai 2026, 20:02 UTC

Câștiguri

Vertex Pharmaceuticals Reiterates 2026 Guidance

4 mai 2026, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 1Q Net $1.03B >VRTX

4 mai 2026, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 1Q Rev $2.99B >VRTX

4 mai 2026, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 1Q Adj EPS $4.47 >VRTX

4 mai 2026, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 1Q EPS $4.02 >VRTX

12 feb. 2026, 21:13 UTC

Câștiguri

Vertex Pharmaceuticals Guidance Includes Immaterial Cost Impact From Tariffs in 2026 >VRTX

12 feb. 2026, 21:13 UTC

Câștiguri

Vertex Pharmaceuticals Sees FY26 Rev $12.95B-$13.1B >VRTX

12 feb. 2026, 21:01 UTC

Câștiguri

Vertex Pharmaceuticals 4Q Rev $3.19B >VRTX

12 feb. 2026, 21:01 UTC

Câștiguri

Vertex Pharmaceuticals 4Q Net $1.19B >VRTX

12 feb. 2026, 21:01 UTC

Câștiguri

Vertex Pharmaceuticals 4Q EPS $4.65 >VRTX

12 feb. 2026, 21:01 UTC

Câștiguri

Vertex Pharmaceuticals 4Q Adj EPS $5.03 >VRTX

3 nov. 2025, 21:05 UTC

Câștiguri

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

3 nov. 2025, 21:02 UTC

Câștiguri

Vertex Pharmaceuticals 3Q EPS $4.20 >VRTX

3 nov. 2025, 21:02 UTC

Câștiguri

Vertex Pharmaceuticals 3Q Adj EPS $4.80 >VRTX

3 nov. 2025, 21:02 UTC

Câștiguri

Vertex Pharmaceuticals 3Q Net $1.08B >VRTX

3 nov. 2025, 21:02 UTC

Câștiguri

Vertex Pharmaceuticals 3Q Rev $3.08B >VRTX

5 aug. 2025, 20:44 UTC

Câștiguri

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 aug. 2025, 18:17 UTC

Câștiguri

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 aug. 2025, 15:25 UTC

Câștiguri

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5 aug. 2025, 14:12 UTC

Câștiguri

Vertex Stock Tumbles After Strong Earnings. What's Spooking Investors. -- Barrons.com

5 aug. 2025, 11:27 UTC

Câștiguri

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 aug. 2025, 10:55 UTC

Câștiguri

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 aug. 2025, 10:36 UTC

Câștiguri

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 aug. 2025, 10:18 UTC

Câștiguri

Vertex Stock Tumbles 15% After Strong Earnings. What's Spooking Investors. -- Barrons.com

Comparație

Modificare preț

Vertex Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

25.51% sus

Prognoză pe 12 luni

Medie 565.3 USD 25.51%

Maxim 641 USD

Minim 436 USD

În baza a 23 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruVertex Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

23 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 23 analiști care au acordat evaluări ale acțiunilor Vertex Pharmaceuticals Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

428.545 / 498.65Suport & Rezistență

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

20 / 345 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.